Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 10/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23609421 | 0.89 | SSTR4 (0.50) | SSTR4SSTR1HCRTR1HCRTR2 | |
| SCHEMBL6926433 | 0.84 | LRRK2 (0.54) | SSTR4SSTR1HCRTR1HCRTR2 | |
| SCHEMBL20147460 | 0.83 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL20071111 | 0.78 | SSTR4 (0.45) | SSTR4HCRTR1HCRTR2 | |
| SCHEMBL4111572 | 0.75 | HTR1A (0.55) | SSTR4 | |
| SCHEMBL15468357 | 0.75 | PDE10A (0.57) | — | |
| SCHEMBL15696551 | 0.75 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL15800230 | 0.75 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL10370885 | 0.75 | HCRTR2 (0.40) | SSTR4SSTR1HCRTR1HCRTR2 | |
| SCHEMBL13162851 | 0.74 | SLC6A4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SSTR4 2604/4885SSTR1 3071/4885HCRTR1 2257/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SSTR4 2604/4885SSTR1 3071/4885HCRTR1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.